CN103254281B - Tubulin polymerizing agent polypeptides 6 and application thereof - Google Patents
Tubulin polymerizing agent polypeptides 6 and application thereof Download PDFInfo
- Publication number
- CN103254281B CN103254281B CN201310208863.3A CN201310208863A CN103254281B CN 103254281 B CN103254281 B CN 103254281B CN 201310208863 A CN201310208863 A CN 201310208863A CN 103254281 B CN103254281 B CN 103254281B
- Authority
- CN
- China
- Prior art keywords
- tubulin
- tubulin polymerization
- polymerization agent
- application
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the field of medicine, particularly polypeptides capable of inhibiting polymerization of tubulin and treating acute lymphatic leukemia. The sequence is CRALERLV which is a brand-new sequence. The polypeptides can inhibit polymerization of tubulin in vitro on the 1 micromole level and enhance the survival rate of tumor bearing mice in an in-vivo test, thereby having potential new drug development value.
Description
Technical field
The present invention relates to tubulin polymerization agent polypeptide 6 and application thereof, be specifically related to have the polypeptide that promotes tubulin polymerization, treatment acute lymphoblastic leukemia.
Background technology
Acute lymphoblastic leukemia (ALL) is a kind of carrying out property malignant disease, it is characterized by a large amount of lymphoblastic neocytes that is similar to.These cells can be found in blood, marrow, lymphoglandula, spleen and other organ.Acute lymphoblastic leukemia accounts for 80% of acute leukemia, and sickness rate peak is between 3 years old to 7 years old.ALL also can betide grownup, accounts for all grownups leukemic 20%.Along with the going deep into of medical research, the understanding of acute lymphoblastic leukemia and treatment are had made great progress in recent years.Wherein, tubulin is being played the part of key player in acute lymphoblastic leukemia.
Microtubule is the chief component of cytoskeleton, by
α-tubulin and
β-tubulin heterodimer forms, and has the feature of hollow tubular structure.In addition, a kind of in addition
γtubulin, it is not the moiety of microtubule, but participates in the assembling of microtubule.Microtubule has the dynamics of Aggregation and disaggregation, in maintaining the processes such as cellular form, cell fission, signal transduction and material conveying, plays an important role.Microtubule becomes spindle body in prophase of cell division polymerization, and spindle body draws karyomit(e) in mitotic division, to the two poles of the earth, moves in two daughter cells, completes cell proliferation.The assembling process of microtubule be α-and 'beta '-tubulin opposite sex dimer between noncovalent interaction closely, this process is driven by GTP hydrolysis.Opposite sex dimer constantly, in the positive pole growth of microtubule, shrinks at negative pole, and maintains dynamic stability.When the dynamic stability of microtubule is destroyed, the mitotic division process of cell is just likely prevented from, thereby causes necrocytosis.Because microtubule has extremely important effect in cell fission, now become one of important target spot of antitumor drug research.
Antitubulin has two kinds of sorting techniques.A kind of is to be divided into two types according to the difference of mechanism of action: the tubulin depolymerizing agent that 1. suppresses tubulin polymerization; 2. promote the tubulin polymerization agent of tubulin polymerization.
Promote the tubulin polymerization agent of tubulin polymerization to have the compounds such as taxol, be used for oncotherapy.This compounds is characterized in acting on the tubulin depolymerizing agent in the vinealeucoblastine(VLB) site of microtubule.Research shows, after taxol and cells contacting, can rupture by induce dna, causes apoptosis.In addition, it can also inducing cell in tumour necrosis factor
α(TNF-
α) expression of gene, improve protein, comprise the phosphorylation level of MAP kinases and the kinase whose tyrosine residues of Raf-1.In December, 1992, U.S. FDA has been ratified the treatment of taxol for mammary cancer and ovarian cancer.Its application clinically that taxol has had 3 important effects limit: (1) taxol content in several Chinese yew genus plants is very low, is restricted source; (2) water-soluble relatively low, receptivity is poor; (3) the cancer cells meeting overexpression P-glycoprotein of crossing by taxol treatment, has multidirectional resistance.
Therefore, need to develop good water solubility, the little tubulin polymerization agent of side effect is used for the treatment of acute lymphoblastic leukemia.Tubulin polymerization agent comprises macromole and small molecules.The preparation of macromole polymerizing agent and use have limited their development, and for example recombinant human tubulin promotes the Half-life in vivo of the factor to only have 4 minutes.Much successful small molecules polymerizing agents can promote the vigor of tubulin in nmole level, but small molecules polymerizing agent lacks specificity, if long-term in chronic disease, use the specific tubulin polymerization agent of shortage can produce larger side effect.Thereby from the application point of tubulin polymerization agent, the acute lymphoblastic leukemia of usining is correct selection as research object.At Acute response stage, body can tolerate inhibition short-term, tubulin wide spectrum polymerizing agent Normal Physiological Function, makes the physiological structure of critical tissue's organ avoid destroying simultaneously, has increased chances of survival.
Tubulin polymerization agent polypeptide 6 in this patent has proved in acute lymphoblastic leukemia effective, has the prospect of developing in other tumor models.
Summary of the invention
goal of the invention
The invention provides brand-new sequence, this sequence tubulin polymerization agent, has good curative effect to acute lymphoblastic leukemia.
technical scheme
tubulin polymerization agent polypeptide 6, is characterized in that its sequence is LSYSMDAG.
The application of tubulin polymerization agent polypeptide 6 in preparation treatment acute lymphoblastic leukemia medicine.
beneficial effect
Utilize solid-phase synthesis chemosynthesis tubulin polymerization agent polypeptide 6, this polypeptide has brand-new sequence, and this polypeptide can external promotion tubulin, treatment acute lymphoblastic leukemia.In endotoxin shock model experiment, successfully increased the survival rate of mouse.The tubulin polymerization agent polypeptide 6 that we find can promote tubulin polymerization vigor simultaneously, and in test, improves tumor-bearing mice survival rate in vivo, has potential new drug development and is worth.
Embodiment
the polypeptide the present invention relates to is synthetic by the raw work in Shanghai.
Embodiment 1
The effect of 6 pairs of external tubulin polymerizations of tubulin polymerization agent polypeptide and depolymerization.
Get fresh cow brain tissue, peel off meninx and large blood vessel, shred, with cold MES damping fluid washing 1-2 time, with every Borneo camphor, organize the ratio of 0.5-1ml to add MES damping fluid, at 4 ℃, use electric homogenizer homogenate; 4 ℃, the centrifugal 1h of 105000g, gets supernatant, adds isopyknic microtubule polymerization damping fluid, 37 ℃ of water bath heat preservation 30min.26 ℃, the centrifugal 1h of 105000g, gets precipitation, adds the cold MES damping fluid of approximately 1/10 homogenate volume, stirs gently or with homogenizer, precipitation is pulverized; Suspension is put to ice bath 30min, precipitation is dissolved completely.By Lowry ' s method, measure protein content (SDS polyamide gels electrophoretic method).Tubulin is diluted to 4-5mg/ml with MES damping fluid, puts in liquid nitrogen and preserves.Get freezing tubulin solution, by normal-temperature water, rush its wall fast, make it to melt, put into ice bath, with MES damping fluid, be diluted to desired concn (2-3mg/ml), add ATP to 1mmol/l.The tubulin solution at once taking out from ice bath of take is " 0 " point in spectrophotometer 350nm setting.Then cuvette is measured at 37 ℃ of temperature to the OD value of tubulin solution, 20-30min, records temperature-light absorption value curve (T-OD curve), in triplicate continuously.
Inhibiting rate calculates: inhibiting rate (%)=(control tube " OD " value-chemical feed pipe " OD " value)/control tube " OD "
Experimental group is established five dosage: 0.75 μ M, 1.5 μ M, 3 μ M, 12 μ M, 24 μ M, and positive controls dose of paclitaxel 3 μ M, blank group adds isopyknic solvent DMSO; Press aforesaid operations and measure light absorption value.As a result, with tubulin polymerization agent polypeptide 6 concentration, increase, polymerization retardation rate raises gradually, illustrates that the tubulin of polymerizing power constantly strengthens with the increase of drug level.
Embodiment 2
The growth of 6 pairs of cultured tumor cells in vitro of tubulin polymerization agent polypeptide and survival IC50.
Adopt MTT colorimetry.By the U937 cell of logarithmic growth, add in 96 well culture plates with 1.0 * 105, cultivate 24h, experimental port, positive drug control wells add respectively Experimental agents tubulin polymerization agent polypeptide 6 and the positive control medicine taxol of different concns; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h,, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, at microplate reader 620nm place, measure absorbance A value, by formula growth of tumour cell inhibiting rate=(1-experimental group light absorption value/control group light absorption value) * 100%.The IC50 that calculates Experimental agents is 8.32 μ M.
Embodiment 3
With vigor in the body of tumor model detection tubulin polymerization agent polypeptide 6.
Set up U937 tumor model, positive control medicine taxol; Blank group adds the solvent of same volume, and experimental group is established 3 dosage: 0.75,1.5 μ M, 3 μ M mg/Kg.After 21 days, observe mouse survival quantity, calculate survival rate.Result demonstration, tubulin polymerization agent polypeptide 6 can be protected small white mouse effectively, improves the survival rate of tumor-bearing mice, and survival rate reaches 66.4%.
SEQUENCE LISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120> tubulin polymerization agent polypeptide 6 and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 8
<212> PRT
<213> artificial sequence
<400> 1
Leu Ser Tyr Ser Met Asp Ala Gly
1 5
Claims (2)
1. tubulin polymerization agent polypeptide 6, is characterized in that its sequence is LSYSMDAG.
2.
claimed in claim 1the application of tubulin polymerization agent polypeptide 6 in preparation treatment acute lymphoblastic leukemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310208863.3A CN103254281B (en) | 2013-05-30 | 2013-05-30 | Tubulin polymerizing agent polypeptides 6 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310208863.3A CN103254281B (en) | 2013-05-30 | 2013-05-30 | Tubulin polymerizing agent polypeptides 6 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103254281A CN103254281A (en) | 2013-08-21 |
| CN103254281B true CN103254281B (en) | 2014-09-03 |
Family
ID=48958534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310208863.3A Active CN103254281B (en) | 2013-05-30 | 2013-05-30 | Tubulin polymerizing agent polypeptides 6 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103254281B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923170A (en) * | 2014-01-17 | 2014-07-16 | 南通诚信氨基酸有限公司 | Polyethylene glycol modified tubulin depolymerization agent polypeptide and its application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109298A2 (en) * | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
-
2013
- 2013-05-30 CN CN201310208863.3A patent/CN103254281B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109298A2 (en) * | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
Non-Patent Citations (7)
| Title |
|---|
| c interaction with brain tubulin.《Journal of Neurochemistry》.2006,第98卷(第3期),973–984. |
| Inna Divinski et al..Peptide neuroprotection through specifi |
| Peptide neuroprotection through specific interaction with brain tubulin;Inna Divinski et al.;《Journal of Neurochemistry》;20060619;第98卷(第3期);973–984 * |
| 吴作基等.微管解聚相关蛋白质Kinesin-13、Stathmin和Katanin.《生命科学》.2008,第20卷(第2期),268-274. |
| 尚海等.微管蛋白抑制剂的研究进展.《药学学报》.2010,第45卷(第9期),1078-1088. |
| 微管蛋白抑制剂的研究进展;尚海等;《药学学报》;20100930;第45卷(第9期);1078-1088 * |
| 微管解聚相关蛋白质Kinesin-13、Stathmin和Katanin;吴作基等;《生命科学》;20080430;第20卷(第2期);268-274 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103254281A (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103254281B (en) | Tubulin polymerizing agent polypeptides 6 and application thereof | |
| CN103288926B (en) | Tubulin polymerization agent polypeptide and application thereof | |
| CN103254287B (en) | A kind of tubulin depolymerizing agent polypeptide and application thereof | |
| CN103254283B (en) | Tubulin polymerizing agent polypeptides and application thereof | |
| CN103265621B (en) | Tubulin depolymerizing agent polypeptide and application thereof | |
| CN103254282B (en) | Tubulin depolymerizing agent polypeptides 5 and application thereof | |
| CN103739680B (en) | A kind of anti-adhesion spot kinase polypeptide and application thereof | |
| CN103923184A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103304632A (en) | Tubulin polymerizing agent polypeptides 2 and application thereof | |
| CN103304633A (en) | Tubulin polymerizing agent polypeptides 1 and application thereof | |
| CN103254284B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN103254289B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
| CN103739678B (en) | Anti-adhesion spot kinase polypeptide and application thereof | |
| CN103923187A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103923173A (en) | Polyethylene glycol modified tubulin polymerization agent polypeptide and its application | |
| CN103923179A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
| CN103923170A (en) | Polyethylene glycol modified tubulin depolymerization agent polypeptide and its application | |
| CN104694520A (en) | Hydrolyzed profibrinolysin polypeptide and application thereof | |
| CN104017052B (en) | about Npas2 protein agonist polypeptide and application thereof | |
| Alkan et al. | Strategic and Innovative Roles of lncRNAs Regulated by Naturally-Derived Small Molecules in Cancer Therapy | |
| CN104045692B (en) | A kind of Npas2 protein agonist polypeptide and application thereof | |
| CN104045691A (en) | Npas2 protein agonist polypeptide and application thereof | |
| CN104004058B (en) | Relevant interleukin-33 inhibitor polypeptide and application thereof | |
| CN111150721A (en) | Calmodulin phosphatase inhibitor and application thereof in tumor resistance | |
| Yang | Treatment of Prostate Cancer with Fucoidan of Low Molecular Weights in Combination with Guanine-rich Oligonucleotide Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG GUANGTAI BIOCHEMISTRY PRODUCT CO., LTD. Free format text: FORMER OWNER: SUZHOU PULUODA BIOLOG SCIENCE + TECHNOLOGY CO., LTD. Effective date: 20140805 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Chuntao Inventor before: Luo Ruixue |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LUO RUIXUE TO: LI CHUNTAO Free format text: CORRECT: ADDRESS; FROM: 215000 SUZHOU, JIANGSU PROVINCE TO: 226600 NANTONG, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140805 Address after: 226600, No. 188, chemical Avenue, fine chemical industrial park, Haian hi tech Zone, Nantong, Jiangsu Applicant after: Nantong Guangtai Biochemical Product Co., Ltd. Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |